Home » Stocks » ALPN

Alpine Immune Sciences, Inc. (ALPN)

Stock Price: $11.55 USD -1.16 (-9.13%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 294.56M
Revenue (ttm) 4.58M
Net Income (ttm) -27.74M
Shares Out 22.28M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $11.55
Previous Close $12.71
Change ($) -1.16
Change (%) -9.13%
Day's Open 12.75
Day's Range 11.39 - 12.99
Day's Volume 171,021
52-Week Range 2.15 - 15.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 2 weeks ago

Although micro-cap stocks don't perform well during an economic downturn, they outperform the market during periods of recovery. Here are 7 stocks to invest in as we head toward a new normal.

Other stocks mentioned: CELH, PI, UPWK, WTRH, YELP, ZUO
Business Wire - 2 weeks ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Executive Leadership Addition and Promotion

Seeking Alpha - 3 weeks ago

Alpine Immune Sciences is a stellar growth bio-stock that is reaching a point of growth inflection. Back in June last year, Alpine secured a highly favorable partnership with AbbVie.

The Motley Fool - 3 weeks ago

Innovation paid off big for investors.

Other stocks mentioned: AQB, CTIC, IBIO
Business Wire - 1 month ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference

Business Wire - 1 month ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

Zacks Investment Research - 1 month ago

Alpine (ALPN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Business Wire - 2 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

Business Wire - 2 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Seeking Alpha - 2 months ago

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire - 2 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update

Business Wire - 4 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Business Wire - 4 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Seeking Alpha - 5 months ago

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Business Wire - 5 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Business Wire - 5 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Business Wire - 6 months ago

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces $60 Million Private Placement

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).

Zacks Investment Research - 6 months ago

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ATNM, PCRX, TBIO
Forbes - 6 months ago

Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.

Other stocks mentioned: CNCE, MRAM, PIXY, SGBX
Zacks Investment Research - 7 months ago

Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

GeekWire - 7 months ago

Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal with pharmaceutical giant AbbVie for its lupus drug.

Benzinga - 7 months ago

Shares of the micro-cap, clinical-stage immune therapy company Alpine Immune Sciences Inc (NASDAQ: ALPN) were advancing strongly Thursday.

24/7 Wall Street - 7 months ago

Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc.

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences.

Zacks Investment Research - 9 months ago

Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 9 months ago

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Alpine Immune Sciences, Inc. (ALPN) CEO.

Zacks Investment Research - 1 year ago

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016.

Other stocks mentioned: BEN, CMS, D, KSS
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.

Seeking Alpha - 1 year ago

Alpine Immune Sciences: A New Name On The Radar

About ALPN

Alpine Immune Sciences focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the tre... [Read more...]

Industry
Biotechnology
CEO
Charles Scoggin
Employees
53
Stock Exchange
NASDAQ
Ticker Symbol
ALPN
Full Company Profile

Financial Performance

In 2019, ALPN's revenue was $1.74 million, an increase of 146.81% compared to the previous year's $705,000. Losses were -$41.85 million, 14.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ALPN stock is "Strong Buy." The 12-month stock price forecast is 21.40, which is an increase of 85.28% from the latest price.

Price Target
$21.40
(85.28% upside)
Analyst Consensus: Strong Buy